What diseases is clofazimine mainly used to treat?

Clofazimine (Clofazimine) was originally developed as an anti-tuberculosis drug, but with the deepening of research, it has shown unique efficacy in the treatment ofleprosy (Hansen's disease). It has now been included in the standard multidrug therapy (MDT) program by the World Health Organization and is one of the core drugs for the treatment of leprosy. Its main mechanism of action is to achieve antibacterial effects by interfering with the cell wall function of mycobacteria and inhibiting their energy metabolism. At the same time, clofazimine also has certain immunomodulatory and anti-inflammatory effects, which makes it potentially valuable in the treatment of diseases related to immune imbalance.

In the treatment of leprosy, clofazimine is mainly used to control the number of bacteria in patients with multibacillary leprosy and reduce the risk of disease transmission and recurrence. It is often used in combination with rifampicin and daflunamide to form a so-called triple therapy. Compared with other drugs, clofazimine is more effective in reducing leprosy reactions and reducing the risk of complications, especially for patients with skin lesions and neuritis. It can also effectively control the inflammatory response during leprosy reactions and prevent further nerve damage, which is an advantage that other anti-leprosy drugs do not have.

In addition to leprosy, clofazimine has been tried in recent years to treat some drug-resistant non-tuberculous mycobacteria (NTM) infections, especially chronic infections caused by Mycobacterium avium complex (MAC). This type of infection is common in immunocompromised patients, especially those with AIDS or those taking long-term immunosuppressive drugs. Clofazimine is regarded as a second-line or auxiliary drug in this type of disease. Its antibacterial spectrum covers some drug-resistant strains. Therefore, it is often used in combination with macrolides and rifampin drugs to enhance the efficacy and reduce the risk of resistance.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine